Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Pathos AI announced a collaboration with pharmaceutical company Bristol Myers Squibb and healthcare AI firm Tempus AI to create artificial intelligence tools aimed at advancing drug development for Alzheimer's disease.
Key points
- Three-party collaboration on AI drug development
- Focus on Alzheimer's research
- Combines expertise across biotech and AI
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Economic Times Tech did the reporting; read the original for the full story.
Read the full story at Economic Times Tech
